AIM ImmunoTech’s Subsidiary Receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to Treat Pancreatic Cancer

NEXT STORY
Global Rare Disease Market is estimated to be US$ 547.5 billion by 2030 with a CAGR of 13.1% during the forecast period – by PMI
PREV STORY
Locus Biosciences completes first-of-its-kind controlled clinical trial for CRISPR-enhanced bacteriophage therapy
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Idera Pharmaceuticals Announces Launch of Global Phase 3 Trial Evaluating IMO-2125 in Combination with Ipilimumab for the Treatment of Anti-PD-1 Refractory Melanoma (ILLUMINATE 301)

EXTON, Pa. and CAMBRIDGE, Mass., March 01, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ...

author_avatar
NASDAQ Market News

Konica Minolta’s Exa Platform Helps Green Bay Radiology Grow While Streamlining Operations

WAYNE, N.J., March 20, 2018 (GLOBE NEWSWIRE) -- Konica Minolta Healthcare Americas, Inc. announces ...

author_avatar
NASDAQ Market News

Cesca Therapeutics Inc. Presents New Data on its Proprietary X-Series™ Cellular Processing Systems

Two posters presented at the International Society for Cellular Therapy (ISCT)2018 Annual Meeting RANCHO ...

author_avatar
NASDAQ Market News